Impact of Dual Antithrombotic Therapy with Aspirin and Rivaroxaban on Secondary Cardiovascular Outcomes

Wei Li; Yi Li; Chen Liu; Jinghao Yuan; Weize Fan; Qing Miao; Xinshun Gu

doi:10.12659/MSM.945457

19 December 2024 : Clinical Research

Impact of Dual Antithrombotic Therapy with Aspirin and Rivaroxaban on Secondary Cardiovascular Outcomes

Wei Li^{ACDE 1*}, Yi Li^{BEF 2}, Chen Liu^{DE 1}, Jinghao Yuan^{BCDE 1}, Weize Fan^{CDEF 1}, Qing Miao^{BEF 1}, Xinshun Gu^{ADE 1}

DOI: 10.12659/MSM.945457

Med Sci Monit 2024; 30:e945457

Authors information Article notes Copyright and License information

Introduction Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Figure 2 Cumulative survival curve of primary efficacy outcome. (The figure was created by GraphPad Prism, version 8.0, GraphPad Software, Inc.).

Back to the Article

Impact of Dual Antithrombotic Therapy with Aspirin and Rivaroxaban on Secondary Cardiovascular Outcomes

Your Privacy